Operating growth is strong; profit conversion remains the test
Issuer-reported values; compare like-for-like reporting bases and periods.
Watch: Monitor conversion of installed capacity into billed production and cash.
Home / Research / Azad Engineering Limited
Operating growth is strong; profit conversion remains the test
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
Issuer-reported values; compare like-for-like reporting bases and periods.
Watch: Monitor conversion of installed capacity into billed production and cash.
Issuer-reported values; compare like-for-like reporting bases and periods.
Watch: Monitor conversion of installed capacity into billed production and cash.
Issuer-reported values; compare like-for-like reporting bases and periods.
Watch: Monitor conversion of installed capacity into billed production and cash.
Issuer-reported values; compare like-for-like reporting bases and periods.
Watch: Monitor conversion of installed capacity into billed production and cash.
Period: quarter and half-year ended 30 September 2026. Stance: WATCH. This is an issuer-source research brief, not a price target or an independent financial audit. Primary numerical exhibit: Azad Engineering November 2026 investor presentation [S1]. Management explanations: [S2]. The transcript is referenced and independently paraphrased, not reproduced.
The investment question: Can six newly commissioned customer-dedicated manufacturing facilities turn installed capacity into billed production quickly enough to offset depreciation, finance costs and working-capital absorption? Operating growth is strong, but reported profit has not yet followed. The answer should be judged against the company's Q3 FY27 throughput and Q4 FY27 revenue-ramp milestones rather than the headline EBITDA margin alone.
| Q2 FY27 consolidated | Value | YoY | Source |
|---|---|---|---|
| Revenue | ₹1,909.4 million | +31.1% | [S1] |
| EBITDA | ₹722.7 million | +37.5% | [S1] |
| EBITDA margin | 37.9% | — | [S1] |
| PAT | ₹309.3 million | -5.2% | [S1] |
| H1 FY27 consolidated | Value | YoY | Source |
|---|---|---|---|
| Revenue | ₹3,635.3 million | +28.6% | [S1] |
| EBITDA | ₹1,366.4 million | +34.3% | [S1] |
| PAT | ₹660.9 million | +6.5% | [S1] |
Five decision takeaways
Decision: WATCH the conversion of commissioned capacity into customer-accepted shipments. Azad supplies high-precision engineered components to demanding OEMs in energy, oil and gas, aerospace and defence. Its customer-dedicated manufacturing footprint may support multi-year production relationships, but qualification timing and utilization are critical to the investment case. Q2 demonstrates demand and operating profitability; it does not yet demonstrate the earnings or free-cash-flow yield of the expanded asset base.
What valuation would demand. A premium multiple would need evidence of repeat orders, yield stability, on-time OEM qualifications, rising cash generation and declining incremental capex per unit of revenue. If the factories remain underutilized or require further financing, the same headline revenue growth could deserve a materially lower multiple. The analytical burden is to distinguish contracted opportunity from invoiced revenue and cash retained after working capital.
The November investor presentation [S1] provides both consolidated and standalone tables. The two bases must not be combined in a single growth calculation. Consolidated Q2 revenue of ₹1,909.4 million rose 31.1% and EBITDA of ₹722.7 million rose 37.5%; PAT declined 5.2% to ₹309.3 million. Consolidated H1 revenue was ₹3,635.3 million, EBITDA ₹1,366.4 million and PAT ₹660.9 million, growing 28.6%, 34.3% and 6.5% respectively.
| Standalone measure | Q2 FY26 | Q2 FY27 | Reading |
|---|---|---|---|
| Revenue, ₹million | 1,426.7 | 1,878.0 | +31.6% |
| EBITDA, ₹million | 513.8 | 704.4 | +37.1% |
| EBITDA margin | 36.0% | 37.5% | +1.5 percentage points |
| PAT, ₹million | 330.0 | 308.2 | -6.6% |
For H1 standalone, revenue advanced from ₹2,771.8 million to ₹3,583.2 million, EBITDA from ₹999.0 million to ₹1,345.1 million and PAT from ₹629.9 million to ₹671.7 million [S1]. This is not an adjusted-PAT claim: these are the issuer-presented reported measures. EBITDA is a company-presented operating measure and is not a substitute for statutory profit or operating cash flow.
The [S2] identifies several below-EBITDA headwinds in standalone Q2: other income fell to about ₹4.7 crore from ₹12.7 crore; depreciation rose to about ₹21.8 crore from ₹10.9 crore; finance cost rose to about ₹12.2 crore from ₹6.4 crore. Management also describes employee expense of approximately ₹50.3 crore versus ₹32.5 crore as hiring preceded utilization. These figures explain the earnings bridge but should not be casually labeled exceptional or added back to create an invented normalized profit.
Azad's standalone H1 mix was heavily weighted to energy and oil and gas. The issuer presentation reports approximately ₹2,904.6 million of H1 revenue from that category, about 81.1% of total, and approximately 16.8% from aerospace and defence [S1]. Management describes H1 energy/oil-and-gas growth of 28.5% and aerospace/defence growth of 28.3% [S2]. These are two separate end-market drivers but they share the common challenge of complex OEM qualifications and capacity utilization.
Exports represented approximately 88% of H1 standalone revenue, down from approximately 93.9% in the comparable half-year, while the domestic contribution increased to about 12% from 6.1% [S1]. The domestic shift was linked by management to indigenization work, including BHEL-related opportunities [S2]. A larger domestic share may diversify routes to market, but the absolute economic return of those orders still depends on pricing, machining complexity, production yield and working capital.
The most useful segment test next quarter is not simply reported sales growth. It is whether revenue and contribution from newly commissioned capacity become visible without a disproportionate increase in scrap, rework, inventory or receivables. The accepted sources do not provide a complete audited segment-level return-on-capital bridge; no such figure is invented.
Management said that all six customer-dedicated lean facilities had been commissioned, including two GE Vernova facilities inaugurated in September 2026. The approximately 44,800-square-metre footprint serves four named OEMs: Mitsubishi Heavy Industries, GE Vernova, Siemens Energy and Baker Hughes [S2]. Commissioning is a necessary milestone, not proof of full utilization. Management describes multiple parallel customer delta qualifications and a setup phase involving staff, tooling, consumables and production readiness.
The stated timetable is throughput beginning in Q3 FY27, a revenue ramp from Q4 FY27 and all plants fully ramped by Q2 FY28 [S1][S2]. Management also describes a Baker Hughes/Nuovo Pignone supply arrangement extended to 2030 and a BHEL two-year rate contract of approximately ₹52.68 crore [S2]. A rate contract should not be conflated with unconditional, fully delivered revenue. Defence-engine assembly opportunities remain subject to testing and program milestones.
| Management milestone | Nature | Verification needed |
|---|---|---|
| Six facilities commissioned | Management-reported achieved milestone | Customer qualification and billed output |
| Q3 FY27 throughput | Forward-looking timetable | Production, acceptance and dispatch evidence |
| Q4 FY27 ramp | Forward-looking timetable | Sequential revenue and margin contribution |
| Full ramp by Q2 FY28 | Forward-looking timetable | Utilization and return on deployed capital |
| FY28 exit run-rate >₹1,300 crore | Management ambition | Quarterly annualized realized sales, not capacity alone |
The discussion is a management account. This report does not claim independent customer confirmation or reproduce third-party transcript passages.
The financial challenge is a classic front-loaded manufacturing investment cycle: factories, specialized machines, qualified workers and inventories are funded before full output is billed. Management states that approximately ₹251 crore of assets were capitalized during H1 FY27 [S2]. That amount is a capitalization statement, not a complete audited cash-capex number for the same period; cash spending and capitalization dates can differ.
The Q2 standalone income statement already reflects the higher asset and funding burden. Depreciation of approximately ₹21.8 crore versus ₹10.9 crore a year earlier and finance cost of approximately ₹12.2 crore versus ₹6.4 crore illustrate the cost of the expansion [S2]. Management cites EBITDA/finance-cost coverage around 5.8 times; this is an issuer-described operating coverage indicator, not a substitute for a debt maturity or liquidity analysis.
A responsible investor should demand the statutory cash-flow statement, debt schedule and project-level capex-to-billing bridge before assigning a cash-flow multiple. Management's claim that infrastructure is ready is relevant operational evidence, but not proof that capital has earned its cost of capital.
Bull case — timely qualification and utilization. The six commissioned facilities begin delivering accepted units through Q3 FY27, sequential billing accelerates from Q4 FY27, and incremental revenue is earned on a largely installed fixed-cost base. EBITDA margin holds despite rising production complexity, and the below-EBITDA burden becomes a smaller share of revenue. The essential confirmation is higher cash-generating output, not the management revenue-run-rate aspiration alone.
Base case — staggered customer ramps. Some OEM lines qualify faster than others. Revenue continues growing but capitalized depreciation and finance costs limit near-term PAT growth. Working capital remains elevated while deliveries ramp. The stock's investment appeal would depend on the price paid relative to realistic utilization and cash conversion, which cannot be quantified here without verified valuation inputs.
Bear case — capacity remains ahead of revenue. Qualification delays, customer schedule changes or yield issues keep assets underutilized. Employee, depreciation and finance expenses remain elevated while sales growth slows. PAT and cash conversion deteriorate despite positive EBITDA. The most important falsifiers are missed Q3/Q4 milestones, persistent negative cash conversion, or further debt-funded capex without proportionate customer billing.
Investor fit: a patient, risk-aware positional investor willing to monitor quarterly execution may find the company worth following. An investor requiring immediate PAT momentum, demonstrated free cash flow or a verified valuation margin of safety does not yet have that evidence in this issuer-source brief.
| Monitoring test | Next evidence | What changes the thesis |
|---|---|---|
| Revenue ramp | Q3 FY27 and Q4 FY27 standalone/consolidated sales | Accepted output from commissioned facilities |
| Operating leverage | EBITDA and gross margins on same accounting basis | Growth without quality or cost deterioration |
| Net earnings | PAT, other income, depreciation and finance cost | Operating gains translate below EBITDA |
| Working capital | Inventory, receivables and cash flow | Sales convert to cash rather than stock |
| Customer qualifications | Management milestone updates | Lines begin regular commercial deliveries |
| Balance-sheet resilience | Debt, liquidity and funding disclosures | No disproportionate financing burden |
Entry discipline: WATCH rather than issue an unconditional buy. Establish an independently sourced current valuation and an appropriate margin of safety before entry; do not derive an entry price from the company's run-rate aspiration. A better risk-reward setup would combine evidence of the Q4 ramp with cash conversion and a defensible valuation. Avoid chasing a single optimistic quarterly announcement without checking the cost of capital.
Catalysts: customer qualification completions, first meaningful deliveries from new lines, rising sequential revenue and improving profit conversion. Risks: OEM concentration, ramp slippage, machining yields, working capital, leverage, FX and program timing. Review cadence: after Q3 FY27 results and again after Q4 FY27, with a full cash-flow and debt update as soon as statutory disclosures are available.
Source register and limitations. S1 — Azad Engineering investor presentation for quarter and half-year ended 30 September 2026, filed November 2026. . All analysis is original paraphrase of accepted company materials. The presentation is the numerical anchor; the transcript supplies management explanations. The latter is hosted by a third-party transcript provider, and its text is not republished. This brief does not independently certify issuer claims, forecast demand, verify customer orders, reconstruct cash flows, or establish a market valuation. Reported and management-forecast figures are explicitly distinguished.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=141ce341-53e6-49aa-968f-cf41f8e6e3ba.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.